Journal
ENDOCRINE CONNECTIONS
Volume 10, Issue 1, Pages R13-R24Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/EC-20-0487
Keywords
hypercalcemia; malignancy; parathyroid hormone-related peptide; humoral
Categories
Ask authors/readers for more resources
Cinacalcet, an orally taken agent, has the potential to effectively reduce symptoms associated with malignancy-associated hypercalcemia and maintain normal serum calcium levels, impacting morbidity and potentially increasing survival rates. Further studies are needed to explore its efficacy in normalizing calcium levels, improving quality of life, and influencing survival in MAH patients.
Palliation of symptoms related to malignancy-associated hypercalcemia (MAH) is essential and clinically meaningful for patients, given the continued poor prognosis, with high morbidity and mortality associated with this disease process. Historically, agents have been temporizing, having no impact on patient morbidity nor survival. We suggest that cinacalcet can be an efficacious agent to be taken orally, reducing patients' time in the hospital/clinic settings. It is well-tolerated and maintains serum calcium levels in the normal range, while targeted cancer treatments can be employed. This has a direct, major impact on morbidity. Maintaining eucalcemia can increase quality of life, while allowing targeted therapies time to improve survival. Given that our case (and others) showed calcium reduction in MAH, there is promising evidence that cinacalcet can be more widely employed in this setting. Future consideration should be given to studies addressing the efficacy of cinacalcet in calcium normalization, improvement of quality of life, and impact on survival in patients with MAH. Though the exact mechanism of action for cinacalcet's reduction in calcium in this setting is not currently known, we can still afford patients the possible benefit from it.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available